Investigation of the Pharmacokinetics, Safety, and Tolerability of Vericiguat (BAY1021189) in Subjects With Hepatic Impairment (Classified as Child Pugh A or B) and in Age-, Weight-, and Gender-matched Healthy Subjects Following a Single Oral Dose in a Single-center, Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification
Latest Information Update: 28 Jan 2021
At a glance
- Drugs Vericiguat (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Bayer
Most Recent Events
- 28 Jan 2021 New trial record